Angiogenesis Inhibitors: An Update – Can Iressa and Thalomid Rejuvenate the Angiogenesis Inhibitor Class?
Introduction: Despite dozens of angiogenesis inhibitors being investigated in clinical trials, they have failed to live up to expectations and the class has suffered a number of high profile failures. However, there are several promising angiogenesis inhibitors in late stage development, in particular, AstraZeneca’s Iressa and Celgene’s Thalomid. This brief examines the key angiogenesis inhibitors, the problems encountered by the class and what pharmaceutical companies need to do to avoid these pitfalls. Scope: * Overview of angiogenesis inhibitors * Profiles of key angiogenesis inhibitors that have failed clinical trial and those in late-stage development * Reasons for the past failures of angiogenesis inhibitors * Key recommendations to avoid the pitfalls. Report Highlights: Angiogenesis inhibitors have been beset with problems. To date, only one agent has been approved in just one market. One of the main reasons for poor performance of the drug class has been poor clinical trial des
Related Questions
- Angiogenesis Inhibitors: An Update - Can Iressa and Thalomid Rejuvenate the Angiogenesis Inhibitor Class?
- Is Aqueous Logic Inhibitor /Protector compatible with competitors’ inhibitors?
- Is Aqueous Logic Inhibitor /Protector compatible with competitors’ inhibitors?
- Is System Inhibitor compatible with Fernox and Sentinel inhibitors?
- What are inhibitors & how do they work?
- What are inhibitors & how do they work?
